Lpath Inc. (Nasdaq: LPTN) received a $1.45 million two-year grant from the Defense Medical Research and Development Program to study Lpathomab in treating neuropathic pain. Shares of the biotechnology firm leaped $1.22 to $3.30.
Lpath receives $1.45 million grant
June 20, 2016 at 13:31 PM EDT
